Longboard Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin R. Lind
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4275 Executive Square La Jolla CA United States of America 92037
- IPO Date
- Mar 12, 2021
- CIK
- 0001832168
- Website
- longboardpharma.com
- Similar Companies
- Business
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, particularly developmental and epileptic encephalopathies (DEEs) such as Dravet syndrome and Lennox-Gastaut syndrome; its lead product candidate, bexicaserin (LP352), a selective 5-HT2C receptor superagonist, has completed Phase 1b/2a trials, received FDA Breakthrough Therapy Designation for DEE-associated seizures, Rare Pediatric Disease Designation and Orphan Drug Designation for Dravet syndrome, and advanced into Phase 3 trials including the DEEp SEA Study for Dravet syndrome and DEEp OCEAN Study for DEEs; the company also develops LP659, an S1P receptor modulator for neuroinflammatory and neurological disorders, which has completed Phase 1 single-ascending dose studies. Founded in 2020 as Arena Neuroscience, Inc. and renamed Longboard Pharmaceuticals, Inc. in October 2020, the company is headquartered in La Jolla, California, and targets patients with rare neurological disorders through GPCR-targeted therapies licensed from Arena Pharmaceuticals. In December 2024, Longboard was acquired by H. Lundbeck A/S for approximately $2.6 billion in a strategic transaction completed on December 2, 2024, becoming a wholly owned subsidiary to bolster Lundbeck's neuro-rare disease franchise; prior developments included initiation of global Phase 3 programs in 2024 and positive open-label extension data from the PACIFIC study supporting bexicaserin's profile.
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. – LBPH
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and OB on Behalf of Shareholders
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc. - LBPH
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise
Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company
Longboard Pharmaceutical Stock Soars 51%. It's Being Bought for $2.6 Billion.
Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Longboard Stock Soars on FDA Designations for Epilepsy Drug
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024